Patents by Inventor Susanne Kindermann
Susanne Kindermann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210220442Abstract: A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.Type: ApplicationFiled: March 29, 2021Publication date: July 22, 2021Applicant: Ascendis Pharma Endocrinology Division A/SInventors: Harald Rau, Susanne Kindermann, Torben Leßmann, Grethe Norskov Rasmussen, Ulrich Hersel, Thomas Wegge, Kennett Sprogøe
-
Patent number: 10960053Abstract: A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.Type: GrantFiled: September 28, 2018Date of Patent: March 30, 2021Assignee: Ascendis Pharma Endocrinology Division A/SInventors: Harald Rau, Susanne Kindermann, Torben Leßmann, Grethe Norskov Rasmussen, Ulrich Hersel, Thomas Wegge, Kennett Sprogøe
-
Publication number: 20200261544Abstract: The present invention relates to dry compositions of rhGH polymer prodrug containing a lyoprotectant and, optionally, one or more than one excipient. Such compositions are stable for at least 1 year, when stored at 2-8° C. The invention further relates to methods of manufacturing said compositions, containers comprising such composition as well as a kit of parts.Type: ApplicationFiled: May 5, 2020Publication date: August 20, 2020Applicant: Ascendis Pharma Endocrinology Division A/SInventors: Grethe Nørskov Rasmussen, Susanne Kindermann, Harald Rau, Thomas Wegge
-
Patent number: 10682395Abstract: The present invention relates to dry compositions of rhGH polymer prodrug containing a lyoprotectant and, optionally, one or more than one excipient. Such compositions are stable for at least 1 year, when stored at 2-8° C. The invention further relates to methods of manufacturing said compositions, containers comprising such composition as well as a kit of parts.Type: GrantFiled: February 21, 2018Date of Patent: June 16, 2020Assignee: Ascendis Pharma Endocrinology Division A/SInventors: Grethe Nørskov Rasmussen, Susanne Kindermann, Harald Rau, Thomas Wegge
-
Publication number: 20190192634Abstract: A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.Type: ApplicationFiled: September 28, 2018Publication date: June 27, 2019Applicant: Ascendis Pharma Endocrinology Division A/SInventors: Harald Rau, Susanne Kindermann, Torben Leßmann, Grethe Norskov Rasmussen, Ulrich Hersel, Thomas Wegge, Kennett Sprogøe
-
Patent number: 10098930Abstract: A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.Type: GrantFiled: January 19, 2016Date of Patent: October 16, 2018Assignee: Ascendis Pharma Endocrinology Division A/SInventors: Harald Rau, Susanne Kindermann, Torben Lebmann, Grethe Norskov Rasmussen, Ulrich Hersel, Thomas Wegge, Kennett Sprogoe
-
Publication number: 20180185452Abstract: The present invention relates to dry compositions of rhGH polymer prodrug containing a lyoprotectant and, optionally, one or more than one excipient. Such compositions are stable for at least 1 year, when stored at 2-8° C. The invention further relates to methods of manufacturing said compositions, containers comprising such composition as well as a kit of parts.Type: ApplicationFiled: February 21, 2018Publication date: July 5, 2018Applicant: Ascendis Pharma Endocrinology Division A/SInventors: Grethe Nørskov Rasmussen, Susanne Kindermann, Harald Rau, Thomas Wegge
-
Patent number: 9919033Abstract: The present invention relates to dry compositions of rhGH polymer prodrug containing a lyoprotectant and, optionally, one or more than one excipient. Such compositions are stable for at least 1 year, when stored at 2-8° C. The invention further relates to methods of manufacturing said compositions, containers comprising such composition as well as a kit of parts.Type: GrantFiled: November 1, 2016Date of Patent: March 20, 2018Assignee: Ascendis Pharma Endocrinology Division A/SInventors: Grethe Nørskov Rasmussen, Susanne Kindermann, Harald Rau, Thomas Wegge
-
Publication number: 20170056477Abstract: The present invention relates to dry compositions of rhGH polymer prodrug containing a lyoprotectant and, optionally, one or more than one excipient. Such compositions are stable for at least 1 year, when stored at 2-8° C. The invention further relates to methods of manufacturing said compositions, containers comprising such composition as well as a kit of parts.Type: ApplicationFiled: November 1, 2016Publication date: March 2, 2017Applicant: Ascendis Pharma Growth Disorders Division A/SInventors: Grethe Nørskov Rasmussen, Susanne Kindermann, Harald Rau, Thomas Wegge
-
Patent number: 9511122Abstract: The present invention relates to dry compositions of rhGH polymer prodrug containing a lyoprotectant and, optionally, one or more than one excipient. Such compositions are stable for at least 1 year, when stored at 2-8° C. The invention further relates to methods of manufacturing said compositions, containers comprising such composition as well as a kit of parts.Type: GrantFiled: December 15, 2010Date of Patent: December 6, 2016Assignee: Ascendis Pharma Growth Disorders Division A/SInventors: Grethe Nørskov Rasmussen, Susanne Kindermann, Harald Rau, Thomas Wegge
-
Publication number: 20160206702Abstract: A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.Type: ApplicationFiled: January 19, 2016Publication date: July 21, 2016Applicant: Ascendis Pharma Growth Disorders Division A/SInventors: Harald Rau, Susanne Kindermann, Torben Lebmann, Grethe Norskov Rasmussen, Ulrich Hersel, Thomas Wegge, Kennett Sprogoe
-
Patent number: 8367361Abstract: A method of using O6-alkylguanine-DNA alkyltransferase (AGT) is disclosed for transferring a label from a substrate to a fusion protein comprising the AGT. This allows the detection and/or manipulating of the fusion protein, both in vitro and in vivo, by attaching molecules to the fusion proteins that introduce a new physical or chemical property to the fusion protein. Examples of such molecules are, among others, spectroscopic probes or reporter molecules, affinity tags, molecules generating reactive radicals, cross-linkers, ligands mediating protein-protein interactions or molecules suitable for the immobilisation of the fusion protein.Type: GrantFiled: January 24, 2011Date of Patent: February 5, 2013Assignee: Ecole Polytechnique Federale de LausanneInventors: Kai Johnsson, Susanne Kindermann (née Gendreizig), Antje Keppler
-
Publication number: 20120322721Abstract: The present invention relates to dry compositions of rhGH polymer prodrug containing a lyoprotectant and, optionally, one or more than one excipient. Such compositions are stable for at least 1 year, when stored at 2-8° C. The invention further relates to methods of manufacturing said compositions, containers comprising such composition as well as a kit of parts.Type: ApplicationFiled: December 15, 2010Publication date: December 20, 2012Inventors: Grethe Nørskov Rasmussen, Susanne Kindermann, Harald Rau, Thomas Wegge
-
Publication number: 20110201514Abstract: A method of using O6-alkylguanine-DNA alkyltransferase (AGT) is disclosed for transferring a label from a substrate to a fusion protein comprising the AGT. This allows the detection and/or manipulating of the fusion protein, both in vitro and in vivo, by attaching molecules to the fusion proteins that introduce a new physical or chemical property to the fusion protein. Examples of such molecules are, among others, spectroscopic probes or reporter molecules, affinity tags, molecules generating reactive radicals, cross-linkers, ligands mediating protein-protein interactions or molecules suitable for the immobilisation of the fusion protein.Type: ApplicationFiled: January 24, 2011Publication date: August 18, 2011Applicant: ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNEInventors: Kai Johnsson, Susanne Kindermann (née Gendreizig), Antje Keppler
-
Publication number: 20110112021Abstract: A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.Type: ApplicationFiled: April 29, 2009Publication date: May 12, 2011Applicant: Ascendis Pharma ASInventors: Harald Rau, Susanne Kindermann, Torben Lebmann, Grethe Norskov Rasmussen, Ulrich Hersel, Thomas Wegge, Kennett Sprogoe